Skip to content

The action of mechanism of Naoxin'an capsule on recovery ischemic stroke patient

The action of mechanism of Naoxin'an capsule on recovery ischemic stroke patient

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004893
Enrollment
Unknown
Registered
2021-05-28
Start date
2021-06-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Sponsors

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 45-80 years; 2. Education level >= 6 years; 3. The onset of ischemic stroke within 2 weeks to 6 months; 4. Hachinski ischemia scale score> 4 points; 5. There is at least one cognitive impairment; 6. The basic daily functions are normal, and the daily functions of complex tools can be slightly damaged; 7. The patient has single or multiple cerebral infarction lesions; 8. Volunteer to participate in this trial, the subject or his legal guardian shall sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. White matter lesions with cortical and watershed infarction, hemorrhage, hydrocephalus, and specific causes (such as multiple sclerosis); 2. There are major cognitive dysfunctions (the MMSE score of the Simple Mental State Examination Scale is divided by education level: elementary school 17 points, or patients with depression/severe mental disorders; 7. History of other secondary dementia, epilepsy, etc.; 8. Alcoholism, drug abuse; 9. Accompanied by severe neurological deficits that cannot complete the relevant examinations; 10. Those who have participated in other drug trials within 3 months before being selected; 11. Use other drugs to improve cognitive function such as ChEIs or other psychotropic drugs within the past 3 months; 12. Those who are allergic to the test drug.

Design outcomes

Primary

MeasureTime frame
Auditory Verbal Learning Test;Alzheimer's Disease Rating Scale-Cognitive Part;

Secondary

MeasureTime frame
Mean Diffusivity;Verbal Fluency Test;Montreal Cognitive Assessment;Complex Figure Test;Network Connections;Fractional Anisotropy;Mini-Mental State Examination;Trail Making Test;Symbol Digit Modalities Test;Infarction Volume;Clock Drawing Test;Activities of Daily Living Inventory;

Countries

China

Contacts

Public ContactWang Yanping

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

187237277@qq.com+86 10 64093361

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026